Product/Composition:- | Clotrimazole Vaginal Tablets/Cream |
---|---|
Strength:- | 10 mg, 100 mg, 200 mg (vaginal tablets), 1% (cream) |
Form:- | Vaginal Tablets/Cream |
Reference Brands:- | Mycelex(US); Fungusil(EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Clotrimazole vaginal tablets and cream inhibit fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and damaging fungal cell membranes. They effectively treat vaginal candidiasis, offering benefits like targeted therapy, rapid symptom relief, broad antifungal activity, minimal systemic absorption, and high safety, making them a reliable choice for vaginal fungal infections.
Clotrimazole vaginal tablets and creams are approved in the EU and US for treating vaginal candidiasis. In the EU, brands like Canesten are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality. In the US, FDA-approved clotrimazole vaginal products, including tablets and creams, are backed by comprehensive clinical data and pharmacovigilance requirements. Both regions require detailed dossiers for approval, ensuring product safety and efficacy. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We facilitate efficient market entry for clotrimazole vaginal formulations, helping you meet European and American standards for safe, effective antifungal therapy.